DIADEMA Pharmaceuticals

What DIADEMA Pharmaceuticals does

Diadema Pharmaceuticals (legal name: Diadema Farmaceutici srl) is an Italian private limited company headquartered in Pisa that develops and commercializes patented medical devices and nutraceuticals. The company operates across six therapeutic areas: ophthalmology and neuroprotection, microbiota and intestinal well-being, women's well-being, nutritional supplements, urogenital health, and regenerative medicine. Its portfolio comprises 19 products built on seven registered patented formulations, including BIOINTESTIL (palmarosa essential oil + ginger fiber phytocomplex for gut microbiota restoration), RIBOHYAL (vitamin B2 + hyaluronic acid molecule for ocular delivery), and EMULDROP (melatonin absorption technology). The flagship Eurekol line is positioned as the first eubiotic supplement platform, with specialized variants targeting general gut health, macular degeneration, glaucoma, vitreous body integrity, and iron deficiency. Other notable products include Lacrinova (dry eye treatment), the Lacrisun family (surgical and antioxidant eye drops), Fillergyn gel and mousse (menopausal and intimate care), Re7 (melatonin), and DKstAr (vitamins D3/K2/A).

The business model is a B2B2C approach in which Diadema sells through Italian pharmacies and healthcare professional recommendations, supported by a reserved HCP area on its corporate website. The company maintains a multi-language web presence (Italian, English, Spanish) and pursues R&D through a network of more than 10 strategic partners across ophthalmology, regenerative medicine, and hematology. The company is independently owned with no disclosed external funding rounds or institutional investors, operates with 1-10 employees, and generates revenue through one-time product sales rather than licensing or subscription models. Pricing is not publicly disclosed and follows standard retail pharmacy channels.

Name

DIADEMA Pharmaceuticals

Legal name

DIADEMA Farmaceutici srl

Website

https://diademafarma.it

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Diadema Pharmaceuticals is an Italian private company that develops and sells 19 patented medical devices and nutraceuticals across ophthalmology, gastroenterology, gynecology, nutrition, urogenital health, and regenerative medicine, distributed through Italian pharmacies and healthcare professional channels.

Ownership category

akta.pro rank

Product category

Pharmaceutical & Nutraceutical Products

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Ophthalmic Goods (3851)

akta.pro primary industry

Probiotics & Digestive Health Supplements (CRADAGAF)

Keywords

• Ophthalmic medical devices
• Patented nutraceutical supplements
• Gut microbiota products
• Women's intimate health
• Eubiotic formulations

Headquarters

HQ city

Marina Di Pisa

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Medical Devices and Nutraceuticals Sales: Diadema generates revenue through the development and sale of proprietary medical devices and nutraceutical products. The company sells eye drops (ophthalmology), intimate care products (gynecology), and gut health supplements (gastroenterology). Products are distributed through pharmacies and healthcare professional channels. The company has 19 products across various therapeutic areas.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

DIADEMA Pharmaceuticals (Diadema Farmaceutici) develops and sells patented medical devices and nutraceuticals inspired by precision medicine. The company operates across six therapeutic areas: ophthalmology and neuroprotection, microbiota and intestinal well-being, women's well-being, nutritional supplements, urogenital health, and regenerative medicine. Products are distributed through pharmacies in Italy and recommended by healthcare professionals, with a portfolio of 19 products including the flagship Eurekol eubiotic line, Lacrinova and Lacrisun ophthalmic drops, and Fillergyn women's health products.

Product overview

DIADEMA Pharmaceuticals (Diadema Farmaceutici) is an innovative Italian startup developing medical devices and patented nutraceuticals inspired by precision medicine. The product portfolio spans six therapeutic areas: Ophthalmology and Neuroprotection, Microbiota and Intestinal Well-being, Women's Well-being, Nutritional Supplements, Urogenital Health, and Regenerative Medicine. The core Eurekol line represents the company's flagship eubiotic platform for gut microbiota restoration, with specialized variants targeting specific conditions: Eurekol (general gastrointestinal), Eurekol Vitreo (vitreous body health), Eurekol Macula (retinal/macular health), Eurekol Glau (glaucoma/neuroprotection), and Eurekol Ferro (iron deficiency). The ophthalmology portfolio includes Lacrinova (patented Ribohyal formula eye drops), Lacristar (pharma-grade hyaluronic acid drops), Lacrisun family (surgical/anti-oxidant eye drops), TSP (tamarind-based polymer drops), and Idraxil (eyelid spray). Women's health products include Fillergyn gel and Fillergyn mousse for vaginal/menopausal care. Additional supplements include Re7 (patented melatonin with Emuldrop technology) and DKstAr (Vitamin D3/K2/A combination).

Differentiator

Problem solved

Functional benefit

Brands

• Eurekol: First eubiotic product line for gut microbiota restoration, also addressing ophthalmology and gynecology through gut-eye and gut-vaginal axis connections. Includes Eurekol (general), Eurekol Macula, Eurekol Glau, Eurekol Ferro, Eurekol Vitreo.
• Lacrinova
• Fillergyn
• BIOINTESTIL
• RIBOHYAL

Products and services

• Eurekol A dietary supplement with proven action for resolving intestinal symptoms of bloating, pain, abdominal tension, and diarrhea. The first eubiotic on the market containing patented Biointestil phytocomplex to restore intestinal microbiota balance. Targeted at patients with gastrointestinal disorders.
• Eurekol Vitreo A food supplement formulated to maintain the integrity and transparency of the vitreous body through an innovative approach combining eye health and gut microbiota balance. Contains glycosaminoglycans, hyaluronic acid, glucosamine, chondroitin, and Biointestil. Targeted at patients with vitreous body health concerns.
• Eurekol Macula A dietary supplement formulated to support visual function and retinal health in conditions affecting the macula. Contains vitamins, antioxidants, minerals, neuroprotective substances, and Biointestil for restoring healthy gut microbiota. Targeted at patients with macular degeneration, diabetic retinopathy, and retinitis pigmentosa.
• Eurekol Glau A dietary supplement formulated to support visual function in glaucoma pathology. The first eubiotic designed to counteract oxidative and inflammatory processes involving nerve fibers and the optic nerve. Contains Citicoline Cognizin, homotaurine, vitamins, and Biointestil. Targeted at glaucoma patients.
• Eurekol Ferro The first iron-based eubiotic designed for individuals with iron deficiency. Iron is administered every 48 hours for greater absorption and better tolerability. Contains microencapsulated iron (SunactiveFe), Biointestil, B vitamins, Vitamin C, Vitamin D, and Copper. Targeted at patients with iron deficiency anemia.
• Lacrinova Lubricating and moisturizing eye drops for dry eye treatment up to moderate and severe. Features patented Ribohyal formula that transforms into a gel upon contact with the eye without blurring vision. Contains patented RIBOHYAL molecule combining Vitamin B2 and hyaluronic acid. Targeted at patients with moderate to severe dry eye.
• Idraxil Ophthalmic spray designed to reduce lipid evaporation from the tear film. Applied by closing eyes and nebulizing 2-3 times from approximately 10cm distance. Targeted at patients with evaporative dry eye.
• Lacrisun Lubricating eye drops for prevention and treatment of surgical dry eye, promoting ocular surface repair following trauma. Contains hyaluronic acid (0.1%), amino acids, Vitamin E-TPGS, and Riboflavin. Preservative-free. Targeted at post-surgical and trauma-related dry eye patients.
• Lacrisun TONIC 5% Lubricating eye drops for prevention and treatment of corneal edema. Contains 5% Sodium Chloride, 0.1% Hyaluronic Acid, amino acids, Vitamin E-TPGS, and Riboflavin. Promotes repair of ocular surface following surgery and trauma. Targeted at patients with corneal edema.
• Lacrisun ANTIOX Antioxidant ophthalmic solution formulated to protect the eye from damage caused by light and oxidation. Contains Riboflavin (Vitamin B2), Vitamin E TPGS, MSM, amino acids, and hyaluronic acid. Protects lens from light damage and oxidative stress. Targeted at patients needing antioxidant ocular protection.
• Lacristar Lubricating and moisturizing eye drops for mild and moderate dry eye with 0.4% Hyaluronic Acid at Pharmaceutical Grade purity. 10ml multi-dose bottle without preservatives. Targeted at patients with mild to moderate dry eye.
• Fillergyn gel Vaginal intimate gel designed for atrophic states of the vulvo-vaginal mucosa during menopause. Contains hyaluronic acid, Tea Tree Oil, lactic acid, and MSM. Clinically effective in reducing dryness, burning, and itching. Compliant with EU Regulations 2017/745 and 2017/746. Targeted at menopausal women experiencing vaginal dryness.
• Fillergyn mousse Dermatologically tested cleansing mousse for daily intimate hygiene. Formulated with lactic acid, Tea Tree Oil, and Chamomile. Available in 75ml and 150ml bottles. Maintains physiological pH and protects natural bacterial flora. Targeted at women for daily intimate hygiene.
• TSP Lubricating and moisturizing eye drops for dry eye treatment based on TSP, a natural polymer extracted from Tamarindus indica seed. Available in 10ml multi-dose and 0.5ml single-dose bottles. Muco-mimetic properties make it suitable for all forms of dry eye. Targeted at patients with various forms of dry eye.
• Re7 Melatonin drops with patented Emuldrop technology that improves absorption and increases effectiveness. 15ml drops bottle, preservative-free liquid solution. 5 drops provide 1mg of melatonin. Absorption is 2x higher after 20 minutes and 3x higher after 40 minutes compared to regular melatonin. Targeted at consumers needing sleep support.
• DKstAr Food supplement based on Vitamin D3, Vitamin A, and Vitamin K2 in 120mg chewable microtablets. Formulated with synergistic vitamins for well-being in ophthalmology and gynecology. Supports retinal health, bone health, and vascular health. Targeted at consumers needing vitamin D3, A, and K2 supplementation.

Quantifiable outcome

• RE7 melatonin shows 2x higher absorption after 20 minutes and 3x higher after 40 minutes compared to regular melatonin
• +2 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Ten partnerships are on record, tiered core and supporting.

• TGDcoreStrategic or Co-development PartnerStrategic research and development partner supporting Diadema in adopting innovative production protocols and developing cutting-edge solutions in the pharmaceutical field.
• TissuegraftcoreStrategic or Co-development PartnerStrategic partner in regenerative medicine research and development, supporting innovative treatment development.
• FarmigeacoreStrategic or Co-development PartnerStrategic partner for ophthalmology solutions development, supporting Diadema's eye care product portfolio.
• IromedcoreStrategic or Co-development PartnerStrategic partner for iron deficiency and hematology research, supporting Eurekol Ferro development.
• IFBSsupportingStrategic or Co-development PartnerStrategic partner supporting Diadema's research and development initiatives.
• Omini PharmasupportingStrategic or Co-development PartnerPharmaceutical development partner supporting product formulation and manufacturing.
• GricarsupportingStrategic or Co-development PartnerStrategic partner in pharmaceutical research and development.
• SalixsupportingStrategic or Co-development PartnerPartner supporting gastrointestinal product development and research.
• La Sorgente del BenesseresupportingStrategic or Co-development PartnerWellness-focused partner supporting natural product development and well-being solutions.
• Sightsavers Italia ONLUScoreGTM or Marketing PartnerNon-profit partnership where Diadema supports blindness prevention programs in developing countries with each eye drop sold, creating social impact and brand differentiation.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• SIFI S.p.A. Italian ophthalmology specialty pharmaceutical company developing and commercializing eye care products, including treatments for dry eye, glaucoma, and ocular surface disease — directly comparable to Diadema's Lacrinova, Lacristar, and Lacrisun lines distributed through Italian pharmacies.
• Laboratoires Théa: European ophthalmology specialty pharmaceutical company with a strong portfolio of dry eye, allergy, and surgical eye care products — comparable to Diadema in therapeutic focus and European pharmacy-channel distribution.
• SOOFT Italia S.p.A. Italian ophthalmology pharmaceutical company specializing in eye drops and ocular surface treatments sold through Italian pharmacies — closely comparable to Diadema on geography, distribution model, and ophthalmology product focus.
• Nicox SA: French ophthalmology specialty pharma focused on prescription eye care products, including novel mechanisms and delivery technologies — comparable to Diadema in its ophthalmology focus, patented formulation strategy, and European commercial footprint.

Broad incumbents

• Dompé Farmaceutici S.p.A. Larger Italian pharmaceutical company with a diversified portfolio across multiple therapeutic areas, including ophthalmology — comparable to Diadema in its multi-TA Italian pharma model, but with substantially greater scale and resources.
• Bausch + Lomb (Bausch Health): Global ophthalmology and eye health company with a major dry eye, surgical, and OTC eye drop portfolio — represents the competitive ceiling Diadema faces in ophthalmology and a potential strategic acquirer for its patented delivery technologies.
• Chiesi Farmaceutici S.p.A. Major Italian pharmaceutical group with specialty, hospital, and consumer health businesses including women's health and respiratory — comparable in its multi-TA Italian pharma model and product innovation, though at much larger scale.
• Recordati S.p.A. Established Italian pharmaceutical group with a wide prescription and OTC portfolio, including women's health and gastroenterology products — comparable to Diadema in therapeutic areas (women's health, GI) and Italian heritage, but operating at far greater scale.

Emerging players

• Italfarmaco S.p.A. Italian pharmaceutical company with a portfolio spanning women's health, gastroenterology, and rare diseases — comparable to Diadema in its therapeutic area mix and Italian pharma distribution approach, at a larger scale.
• Actial Farmaceutici (Alflorex): European specialty probiotics company built around a proprietary bacterial strain for gut health (Alflorex/Align) — comparable to Diadema in its evidence-backed probiotics positioning and the way a single proprietary ingredient anchors a brand.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/DFarmaceutici
• LinkedInlinkedin.com/company/diademafarma

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DIADEMA Pharmaceuticals